Catapres-150 Tab

Side Effects of Catapres-150 Tab

Dry mouth, drowsiness, dizziness, headache, constipation, impotence, vivid dreams, urinary retention; dry, itching, burning sensation in the eye; fluid or electrolyte imbalance, GI upset, paralytic ileus, orthostatic hypotension, weakness, sedation, pruritus, myalgia, urticaria, nausea, insomnia, arrhythmias, agitation. Reduced GI motility at times may cause paralytic ileus. Potentially Fatal: Transient hypertension or profound hypotension, respiratory depression, convulsion. Clonidine withdrawal syndrome could be life threatening. Bradycardia, coma and disturbances in conduction (in individuals with preexisting diseases of SA/AV nodes, overdose or on digitalis).

Drug Interactions

Hypotensive action may be potentiated by diuretics and vasodilators. Effects of clonidine antagonised by TCAs and centrally-acting alpha-blockers. May enhance toxicity due to digitalis, lithium. May antagonise oral hypoglycaemics. Potentially Fatal: Hypnosedatives, antihistamines and alcohol may cause excessive drowsiness in patients on clonidine. Withdrawal of clonidine in patients receiving noncardioselective β-blockers may result in rebound BP. Acute severe hypotension following concomitant administration of clonidine and chlorpromazine or haloperidol.

Contraindications

Hypersensitivity. Disorders of cardiac pacemaker activity and conduction. Pregnancy and lactation.

Mechanism of Action

Clonidine stimulates alpha-2 receptors in brain stem which results in reduced sympathetic outflow from the CNS and a decrease in peripheral resistance leading to reduced BP and pulse rate. It does not alter normal haemodynamic response to exercise at recommended dosages. Onset: 2-3 days (transdermal). Duration: Maintained for 8 hr after removal of system (transdermal). Absorption: Well absorbed from the GI tract (oral); peak plasma concentrations after 3-5 hr. Absorbed from the skin (transdermal). Distribution: 20-40% protein bound. Metabolism: Hepatic: 50% of the dose. Excretion: Via urine within 24 hr (as 40-60% as unchanged drug), via faeces (20% of the dose); 6-24 hr (elimination half-life), prolonged to 41 hr in renal impairment.

Special Precautions

Withdraw gradually, renal impairment, tasks that require mental alertness. Cerebrovascular disease, ischaemic heart disease, MI. IV inj should be administered slowly. Occlusive peripheral vascular disorders, history of depression.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.